Bank of America
RYTM icon

Bank of America’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bank of America’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,500
Closed -$364K – 8522
2024
Q4 		$364K Sell
6,500
-3,800
-37% -$210K ﹤0.01% 5775
2024
Q3 		$540K Buy
+10,300
New +$494K ﹤0.01% 5437

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Bank of America's RYTM Position: Q1 2026 in Review

Bank of America increased its Rhythm Pharmaceuticals (RYTM) stake by 180% in Q1 2026, buying an estimated $39.3M and bringing the position to 628,667 shares worth $54.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1523.

Bank of America first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Bank of America held 628,667 shares of Rhythm Pharmaceuticals worth $54.7M as of Q1 2026.
  • Bank of America bought 404,183 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $39.3M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1523 holding.
  • Bank of America first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.